Observational studyFrontiers in immunology2023
Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China.
Observational study in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of the Recurrence of Autoimmune Encephalitis.Annals of clinical and translational neurology · 2026Pooled it
- Dynamic single-cell transcriptomic analysis of peripheral blood mononuclear cells identifies novel biomarkers for autoimmune encephalitis.Molecular psychiatry · 2026Article
- Characteristics of and risk factors for epilepsy after autoimmune and infectious encephalitis.BMC neurology · 2026Article
- Systemic and organ-specific autoantibodies and worse outcomes in autoimmune encephalitis: a multicenter cohort study.Frontiers in immunology · 2026Observational
- Clinical, Electroencephalogram and Imaging Characteristics of Patients With Anti-LGI1 Antibody Encephalitis: A Multicenter Cohort Study.CNS neuroscience & therapeutics · 2025Article
- Efficacy of rituximab as second-line therapy for autoimmune encephalitis: A systematic review and meta-analysis.Heliyon · 2025Article
- Autoimmune encephalitis in Latin America. Clinical features and outcomes in pediatric and adult populations: retrospective cohort of The REAL LABIC Project.Frontiers in neurology · 2025Article
- Abnormal CSF-Specific OCBs in Neuronal Surface Antibody-Associated Autoimmune Encephalitis Differentiating from Viral Encephalitis.Journal of inflammation research · 2025Article
- Cerebrospinal fluid biomarkers for predicting immunotherapy response in autoimmune encephalitis.American journal of translational research · 2025Article
- Autoimmune and infectious encephalitis: development of a discriminative tool for early diagnosis and initiation of therapy.Journal of neurology · 2024Article
- Clinical characteristics and outcomes of patients with antibody-related autoimmune encephalitis presenting with disorders of consciousness: A prospective cohort study.Immunity, inflammation and disease · 2024Article
- Middle-aged predominance and diagnostic delays in anti-LGI1 encephalitis: the role of antibody testing.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective observational study primarily aimed to analyse the clinical characteristics of patients with neuronal surface antibody-mediated autoimmune encephalitis (AE) in China and report their prognosis after immunotherapy. Methods: Clinical characteristics, laboratory or imaging examinations, and treatment outcomes of 103 patients diagnosed with AE between 1 September 2014 and 31 December 2020 were collected. Univariate and multivariate logistic regression analyses were performed to determine the predictors of poor prognosis. Results: Overall, 103 patients were enrolled in the study. The main clinical symptoms included seizures (74.8%), psychiatric and behavior disorders (66.0%), cognitive deficits (51.5%), disturbances of consciousness (45.6%), and movement disorders Conclusions: Different AE subtypes demonstrated different clinical symptom spectra throughout the disease stage. Anti-LGI1 encephalitis and anti-CASPR2 encephalitis were more sensitive to first-line and second-line treatments. Anti-GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.